ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Ceralasertib is on this study

  • The record lists it as a treatment, written “AZD6738”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 16 (day only)“With durvalumab in gastric cancer or melanoma”
  • The role rule says the same.
  • So Ceralasertib's page lists this study under “Testing it”.
3 links0 made here, not in the record8 judgments2 judges (the rules as one: Rule based)2 record changes seen1 read an older version
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT03780608A Study of AZD6738 inCombination With Durvalumabin Patients With RefractorySolid Tumors (Cohort A:Chemotherapy-RefractoryGastric Cancer; Cohort B:Anti-PD(L)Samsung Medical CenterPhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedNov 13 · ClinicalTrials.gov record · Version of 2026-11-13Nov 13 · Rule based · Reading set asideNov 16 · Rule based · Read againRead againCONDITIONSMelanomaThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSCeralasertibEntry “AZD6738”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 16 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDurvalumabIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Nov 13 · changes seen, not judgments
Nov 3CeralasertibClaude Opus 5.5TestedReplaced
Nov 3DurvalumabClaude Opus 5.5BackgroundRead an older version
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 13The record itselfRule based · nightly checkReading set asideCurrent
Nov 16The record itselfRule based · nightly checkRead againCurrent
Nov 16CeralasertibClaude Opus 5.5TestedCurrent
Nov 18CeralasertibRule based · role ruleTestedAgrees
Nov 18DurvalumabRule based · role ruleBackgroundCurrent
As of nowMelanomaRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.